Literature DB >> 25883294

Complete genome sequence of canine papillomavirus virus type 12.

Dan Zhou1, Jennifer Luff2, Siddhartha Paul1, Faris Alkhilaiwi1, Yukari Usuda1, Naidong Wang1, Verena Affolter3, Peter Moore3, Richard Schlegel1, Hang Yuan4.   

Abstract

Papillomaviruses, of the family Papillomaviridae, are epitheliotropic, nonenveloped, circular, double-stranded DNA viruses that contribute to benign and malignant tumors in humans and animals. We report here the whole-genome sequence of canine papillomavirus type 12, found at a pigmented plaque located on the skin of a mixed-breed bloodhound.
Copyright © 2015 Zhou et al.

Entities:  

Year:  2015        PMID: 25883294      PMCID: PMC4400437          DOI: 10.1128/genomeA.00294-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Papillomaviruses are nonenveloped double-stranded DNA viruses that are associated with both benign and malignant tumors in humans and animals. Human papillomaviruses (HPVs) cause cancers in the cervix, vulva, vagina, penis, anus, and oropharynx. In total, HPV infections caused 5.2% of all cancers worldwide in 2002 (1). Papillomavirus (PV) infections are widespread in nature and occur in most mammalian species, as well as in birds and turtles (2). These viral infections are highly host and tissue tropic and are rarely transmitted between species. The existence of relevant mammalian models for PV infections has made possible studies of the evolution, life cycle, and pathogenesis of PVs. The canine model is one of the best systems for studying both epidermal and mucosal PV infections, and the analysis of canine oral papillomavirus type 1 (CPV-1) has been critical to understanding host immunity against papillomavirus infection (3, 4) and viral oncogenesis (5–8). More importantly, the CPV model has contributed significantly to development of the HPV vaccine (9, 10). To date, there are 11 canine PVs whose genomes have been sequenced (11), some of which are associated with subclinical infections that can clinically manifest during immunosuppression. PV infections in immunosuppressed dogs have also been noted to progress to aggressive squamous cell carcinomas. Here, we report the complete genome sequencing of a novel type of canine papillomavirus, designated CPV-12, which was isolated from a solitary pigmented plaque on a mixed-breed bloodhound. The viral DNA was isolated from this tumor using routine methods. Initially, PCR with general primers was used to amplify potential PV genome fragments. The sequencing of the products revealed an unknown CPV type. To further pursue the type of CPV present, we used rolling circle amplification to generate the complete viral genome. The amplified viral genome was digested with BamHI, cloned into the BamHI site of the vector pUC19, and sequenced using primer walking-enabled sequencing of the entire viral genome from both directions. The analysis of the viral sequence was performed using ABI 3730xl DNA-analyzing instruments (Applied Biosystems) for capillary electrophoresis and fluorescent dye terminator detection. The Vector NTI Advance 10 software (Invitrogen, USA) was used to assemble the sequence contigs containing high-quality trace files. The complete genome sequence of CPV-12 is 7,890 bp. Similar to other papillomaviruses, CPV-12 has all of its open reading frames (ORFs) on the same coding strand of its circular double-stranded DNA genome. CPV-12 has seven ORFs that encode five early (E) proteins, E1, E2, E4, E6, and E7. In addition, there are two late (L) proteins, L1 and L2. The L1 gene is the most conserved gene within the papillomavirus genome and has therefore been used for the identification of new PV types. A new PV isolate is recognized if the DNA sequence of the L1 ORF differs by >10% from the closest known PV type (2). The L1 DNA of CPV-12 is most closely related (81% homology) to CPV-9. These data will facilitate future investigations of the evolutionary characteristics and molecular pathogenesis of CPVs.

Nucleotide sequence accession number.

The complete genome sequence of canine papillomavirus 12 (CPV-12) is available in GenBank under the accession no. JQ754321.
  11 in total

1.  Cell-mediated immune responses to COPV early proteins.

Authors:  Suchitra Jain; Richard A Moore; Davina M Anderson; Gerald W Gough; Margaret A Stanley
Journal:  Virology       Date:  2006-09-01       Impact factor: 3.616

2.  The canine papillomavirus e5 protein signals from the endoplasmic reticulum.

Authors:  Rachel Condjella; Xuefeng Liu; Frank Suprynowicz; Hang Yuan; Sawali Sudarshan; Yuhai Dai; Richard Schlegel
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

3.  Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments.

Authors:  Hans-Ulrich Bernard; Robert D Burk; Zigui Chen; Koenraad van Doorslaer; Harald zur Hausen; Ethel-Michele de Villiers
Journal:  Virology       Date:  2010-03-05       Impact factor: 3.616

4.  Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs.

Authors:  Michael H Goldschmidt; Jeffrey S Kennedy; Douglas R Kennedy; Hang Yuan; David E Holt; Margret L Casal; Anne M Traas; Elizabeth A Mauldin; Peter F Moore; Paula S Henthorn; Brian J Hartnett; Kenneth I Weinberg; Richard Schlegel; Peter J Felsburg
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  An epidermotropic canine papillomavirus with malignant potential contains an E5 gene and establishes a unique genus.

Authors:  Hang Yuan; Shinje Ghim; Joe Newsome; Tania Apolinario; Vanessa Olcese; Mary Martin; Hajo Delius; Peter Felsburg; Bennett Jenson; Richard Schlegel
Journal:  Virology       Date:  2006-10-10       Impact factor: 3.616

6.  Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.

Authors:  H Yuan; P A Estes; Y Chen; J Newsome; V A Olcese; R L Garcea; R Schlegel
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.

Authors:  S Ghim; J Newsome; J Bell; J P Sundberg; R Schlegel; A B Jenson
Journal:  Exp Mol Pathol       Date:  2000-06       Impact factor: 3.362

Review 8.  Papillomaviruses in the causation of human cancers - a brief historical account.

Authors:  Harald zur Hausen
Journal:  Virology       Date:  2009-01-08       Impact factor: 3.616

9.  The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein.

Authors:  Jingang Wang; Dan Zhou; Anjali Prabhu; Richard Schlegel; Hang Yuan
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

10.  Complete genome sequence of canine papillomavirus type 11.

Authors:  Dan Zhou; Jennifer Luff; Yukari Usuda; Verena Affolter; Peter Moore; Richard Schlegel; Hang Yuan
Journal:  Genome Announc       Date:  2014-05-29
View more
  4 in total

1.  Viral genome integration of canine papillomavirus 16.

Authors:  Jennifer Luff; Michelle Mader; Peter Rowland; Monica Britton; Joseph Fass; Hang Yuan
Journal:  Papillomavirus Res       Date:  2019-02-13

2.  New insights into Canis familiaris papillomaviruses genetics and biology: Is the genetic characterization of CPV types and their variants an important clinical issue?

Authors:  Jordana Dantas Rodrigues Reis; Marcus Vinicius de Aragão Batista
Journal:  Genet Mol Biol       Date:  2022-09-12       Impact factor: 2.087

3.  Identification of canine papillomavirus by PCR in Greyhound dogs.

Authors:  Eman A Anis; Linda A Frank; Raquel Francisco; Stephen A Kania
Journal:  PeerJ       Date:  2016-12-08       Impact factor: 2.984

4.  Whole Genomic Analysis and Comparison of Two Canine Papillomavirus Type 9 Strains in Malignant and Benign Skin Lesions.

Authors:  Chia-Yu Chang; Nanako Yamashita-Kawanishi; Sonoka Tomizawa; I-Li Liu; Wei-Tao Chen; Yen-Chen Chang; Wei-Hsiang Huang; Pei-Shiue Tsai; Kinji Shirota; James K Chambers; Kazuyuki Uchida; Takeshi Haga; Hui-Wen Chang
Journal:  Viruses       Date:  2020-07-08       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.